<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Sat, 05 Dec 2009 09:57:00 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Quiet Day</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2279099</guid>
      <description><![CDATA[Good morning. We're set for a positive open helped mostly by strength in overseas markets. Overall, it's a relatively quiet day so far with focus only on interest rates concerns and rising oil prices.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2279099>[More...]</a>]]></description>
      <pubDate>Wed, 11 Jun 2008 15:51:02 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AAUK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AGU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ALVR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ANAD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BWP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CMGI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRDC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSIQ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DCI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DIOD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DRYS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ESLR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ETFC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HOFT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JASO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JBLU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LEH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MCHP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">OXM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PPCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">QSII</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ROYL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNCR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNIC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SOLF</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SPLS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UAUA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2279099</link>
    </item>
    <item>
      <title>Informa Life Sciences "EU Pharmaceutical Law Forum," Brussels, Belgium, May 8-9</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/1722420</guid>
      <description><![CDATA[Informa Life Sciences will be holding its 17th annual &quot;EU Pharmaceutical Law Forum&quot; in Brussels, Belgium, on May 8 and 9.  This conference is billed as the &quot;must attend&quot; meeting for in-house counsel in pharmaceutical companies and lawyers in private pract<a href=http://www.istockanalyst.com/article/viewarticle/articleid/1722420>[More...]</a>]]></description>
      <pubDate>Wed, 16 Apr 2008 06:03:24 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EPC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MDCO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/1722420</link>
    </item>
    <item>
      <title>Biovest International Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize its Drugs and Technologies</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2783381</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPI), today announced that, primarily due to the disruption in the U.S. capital and finance markets which limited access to required funding, the Company has filed a voluntary petition for reorganization. With existing cash flow and the potential for relatively near-term significant business development opportunities for BiovaxID&#174; and AutovaxID™, this action is intended to provide an opportunity for the Company to restore shareholder value and to pay all secured and unsecured creditors. Under protection of the court, Biovest plans to implement a series of initiatives designed to significantly decrease operating expenses and financing costs, and focus cash and resources on its priority programs that will allow the Company to attract key funding/partnering opportunities. Affiliates of the Company, including Hopkins Capital Group, LLC, a major shareholder, have indicated a willingness to provide additional financing to the Company as part of its reorganization plan. A conference call and webcast is scheduled for 4:30 p.m. (EST) this afternoon to further discuss this action.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2783381>[More...]</a>]]></description>
      <pubDate>Mon, 10 Nov 2008 15:30:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2783381</link>
    </item>
    <item>
      <title>Accentia Biopharmaceuticals Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize Its Drug Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2783614</guid>
      <description><![CDATA[Accentia Biopharmaceuticals, Inc. (Pink Sheets:ABPI) today announced that the Company and its subsidiaries have filed voluntary petitions for reorganization. With existing cash flows from subsidiaries and the potential for relatively near-term significant business development opportunities, this action is intended to provide an opportunity for the Company to restore shareholder value and to pay secured and unsecured creditors. Under protection of the court, Accentia plans to implement a series of initiatives designed to significantly decrease operating expenses and financing costs, and focus cash and resources on drug development and other priority programs that will allow the Company to attract key funding/partnering opportunities. Affiliates of the Company, including Hopkins Capital Group, LLC, a major shareholder, have indicated a willingness to provide additional financing to the Company as part of its reorganization plan. A conference call and webcast is scheduled for 4:30 p.m. (EST) this afternoon to further discuss this action.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2783614>[More...]</a>]]></description>
      <pubDate>Mon, 10 Nov 2008 15:29:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2783614</link>
    </item>
    <item>
      <title>Accentia Biopharmaceuticals Announces Pending Delisting from NASDAQ</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2762975</guid>
      <description><![CDATA[Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that the Company elected not to appeal the NASDAQ Stock Market’s Staff determination to delist Accentia’s shares of common stock from the NASDAQ Capital Market. As previously reported, Accentia received notice from the NASDAQ Stock Market dated October 24, 2008, notifying the Company that it is not in compliance with Rule 4310(c)(3)(B), requiring a minimum $35 million market value. As a result, at the opening of business on November 4, 2008, shares of Accentia will open for trading listed on the Pink Sheets, an electronic quotation service for securities traded over-the-counter. Accentia’s stock ticker symbol will remain the same (“ABPI”).<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2762975>[More...]</a>]]></description>
      <pubDate>Mon, 03 Nov 2008 20:19:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2762975</link>
    </item>
    <item>
      <title>Biovest and IDIS Announce Agreement to Launch Named-Patient Program for Anti-Cancer Vaccine in Europe</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2747992</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that it has executed a distribution agreement with IDIS Limited to exclusively supply BiovaxID&#174; (personalized, anti-idiotype cancer vaccine) under a Named-Patient Program in France, Germany, Italy, Greece, Spain and the United Kingdom. IDIS is a leading European drug distributor, and under terms of this agreement, sales of BiovaxID are expected to commence in the first calendar quarter of 2009, with the anti-cancer vaccine being made available to those patients suffering from various B-cell related blood cancers including: chronic lymphocytic leukemia; mantle cell lymphoma; multiple myeloma; and non-Hodgkin’s lymphoma.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2747992>[More...]</a>]]></description>
      <pubDate>Wed, 29 Oct 2008 13:27:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2747992</link>
    </item>
    <item>
      <title>Accentia Biopharmaceuticals to Present at Rodman &amp; Renshaw 10th Annual Healthcare Conference; Company Also Reports On NASDAQ Compliance Plan</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2737290</guid>
      <description><![CDATA[Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it will present at the Rodman &amp; Renshaw 10th Annual Healthcare Conference on November 11, 2008 at 10:20 a.m. (EDT) at the New York Palace Hotel in New York City. The Company’s presentation will focus on its BiovaxID&#174; personalized anti-cancer vaccine. Accentia’s majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), recently reported encouraging BiovaxID Phase 3 clinical trial results for the treatment of non-Hodgkin’s lymphoma, and the Company is now progressing with plans to seek approvals in the U.S., Europe and other international countries.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2737290>[More...]</a>]]></description>
      <pubDate>Fri, 24 Oct 2008 21:11:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2737290</link>
    </item>
    <item>
      <title>Biovest Announces $1.6M in Federal Funding Appropriated for Groundbreaking Cancer Vaccine &amp; Skin/Bone/Tissue Repair Research</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2729980</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI) today announced that the U.S. Federal Government has approved the appropriation of $1.6 million in biomedical research funds for Fiscal Year 2009 for the Defense Department's Cancer Immunotherapy and Cell Therapy Initiative, which is intended to support research into new applications for the AutovaxID™ instrument, Biovest's fully-automated cell-manufacturing device to cost-effectively and efficiently manufacture difficult-to-produce therapeutic proteins and personalized vaccines, including vaccines targeting cancers.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2729980>[More...]</a>]]></description>
      <pubDate>Wed, 22 Oct 2008 18:57:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2729980</link>
    </item>
    <item>
      <title>Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2686607</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today provided an update on its personalized, anti-cancer vaccine, BiovaxID&#174;, including reporting clinically and statistically significant data from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial for the treatment of indolent follicular non-Hodgkin’s lymphoma, an often fatal blood cancer. After a recent meeting with the FDA, the Company closed the clinical trial, unblinded the patients, and analyzed the disease-free survival in both arms through June 30, 2008. The Company has committed to provide the FDA with a detailed clinical report based on this end-of-study data, including statistical analysis, prior to the next meeting in order to discuss a petition to treat all patients in the clinical trial with BiovaxID and to seek Accelerated Approval under subpart E. Originally, the study was intended to follow patients in both arms after unblinding for the purpose of determining overall survival, but based on the trial results, the Company now believes that it would be unethical to withhold BiovaxID from control patients, and that the study, therefore, is closed. Beyond the Company’s U.S. strategy, Biovest disclosed plans regarding preparations to seek approvals in Europe (EU and select non-EU countries), Asia and Australia.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2686607>[More...]</a>]]></description>
      <pubDate>Tue, 07 Oct 2008 15:11:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2686607</link>
    </item>
    <item>
      <title>Accentia Biopharmaceuticals Receives NASDAQ Notice</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2655547</guid>
      <description><![CDATA[Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it received notice from the NASDAQ Stock Market dated September 22, 2008, notifying the Company that it has fallen below the minimum market capitalization required by the NASDAQ Capital Market. In order to demonstrate compliance with Rule 4310(c)(3)(B), Accentia needs to maintain a minimum $35 million market value for at least 10 consecutive days before October 22, 2008. If the Company does not regain compliance by October 22, 2008, the NASDAQ staff will notify the Company of its non-compliance. In that event and at that time, the Company may appeal NASDAQ’s delisting determination to a NASDAQ Listing Qualifications Panel. This notification has no effect on the listing of Accentia’s common stock at this time.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2655547>[More...]</a>]]></description>
      <pubDate>Fri, 26 Sep 2008 21:30:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2655547</link>
    </item>
    <item>
      <title>Accentia Reports Fiscal Third Quarter Financial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2515045</guid>
      <description><![CDATA[Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that the Company has filed its Quarterly Report (Form 10-Q) with the SEC, reporting the results of its operations, including consolidated results with its majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), for its third fiscal quarter ended June 30, 2008.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2515045>[More...]</a>]]></description>
      <pubDate>Thu, 14 Aug 2008 21:36:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2515045</link>
    </item>
    <item>
      <title>Biovest Joins in the Formation of the Joint U.S.-Norway Cancer Research Program, a Collaborative Effort with Plans to Present to NCI and the U.S. Military Healthcare System</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2476258</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that Biovest has been designated one of the charter members of the Joint U.S.–Norway Cancer Research Program, a collaboration among leading pharmaceutical and biotechnology companies and research organizations with the vision of transforming world-class cancer diagnostics and treatments to improve and extend the lives of cancer patients.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2476258>[More...]</a>]]></description>
      <pubDate>Tue, 05 Aug 2008 13:37:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2476258</link>
    </item>
    <item>
      <title>Form  4          ACCENTIA BIOPHARMACEUTIC  For: Aug 11  Filed by: ODONNELL FRANCIS E JR (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2508735</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2508735>[More...]</a>]]></description>
      <pubDate>Wed, 13 Aug 2008 13:02:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2508735</link>
    </item>
    <item>
      <title>Form  4          ACCENTIA BIOPHARMACEUTIC  For: Aug 08  Filed by: ODONNELL FRANCIS E JR (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2498513</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2498513>[More...]</a>]]></description>
      <pubDate>Mon, 11 Aug 2008 12:29:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2498513</link>
    </item>
    <item>
      <title>Form  4          ACCENTIA BIOPHARMACEUTIC  For: Aug 06  Filed by: ODONNELL FRANCIS E JR (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2487702</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2487702>[More...]</a>]]></description>
      <pubDate>Thu, 07 Aug 2008 12:32:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2487702</link>
    </item>
    <item>
      <title>Form  4          ACCENTIA BIOPHARMACEUTIC  For: Aug 05  Filed by: ODONNELL FRANCIS E JR (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2481776</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2481776>[More...]</a>]]></description>
      <pubDate>Wed, 06 Aug 2008 12:30:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2481776</link>
    </item>
    <item>
      <title>Form  4          ACCENTIA BIOPHARMACEUTIC  For: Aug 04  Filed by: ODONNELL FRANCIS E JR (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2476366</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2476366>[More...]</a>]]></description>
      <pubDate>Tue, 05 Aug 2008 14:23:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2476366</link>
    </item>
    <item>
      <title>Form  4          ACCENTIA BIOPHARMACEUTIC  For: Jul 31  Filed by: ODONNELL FRANCIS E JR (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2464843</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2464843>[More...]</a>]]></description>
      <pubDate>Fri, 01 Aug 2008 19:01:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2464843</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=ABPI" rel="self" type="application/rss+xml" />
  </channel>
</rss>